pmcc logo smlHere are the staff publications for June 2016.




  • Ager B, Butow P, Jansen J, Phillips KA, Porter D. Contralateral prophylactic mastectomy (CPM): A systematic review of patient reported factors and psychological predictors influencing choice and satisfaction.

Breast 2016;28:107-120.


  • Ameratunga M, McArthur G, Gan H, Cher L. Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.

Journal of Clinical Pharmacy and Therapeutics 2016;41:357-359.


  • Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-             independent mechanism.

Blood 2016;127:3215-24.


  • Bachy E, Estell JA, Van de Neste E, et al. Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.

American Journal of Hematology 2016;91:410-5.


  • Basto M, Sathianathen N, Te Marvelde L, et al. Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the Australian public health system.

BJU International 2016;117:930-9.


  • Boyle SE, Fedele CG, Corbin V, et al. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.

Cancer Research 2016;76:3965-77.


  • Came N, Nguyen V, Westerman D, Harrison S. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.

British Journal of Haematology 2016;173:947-9.


  • Cannioto R, LaMonte MJ, Risch HA, et al. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.

Cancer Epidemiology Biomarkers & Prevention 2016;25:1114-24.


  • Charoenlap C, Imanishi J, Tanaka T, et al. Outcomes of unplanned sarcoma excision: impact of residual disease.

Cancer Medicine 2016;5:980-8.


  • Corry J. Should all mucosal head and neck cancer patients be treated in high volume centres, or can some be appropriately triaged to local centres for treatment.

Journal of Medical Imaging and Radiation Oncology 2016;60:386-8.


  • Cuellar-Partida G, Lu Y, Dixon SC, et al. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.

Human Genetics 2016;135:741-56.


  • Dixon BJ, Chan H, Daly MJ, et al. Three-dimensional virtual navigation versus conventional image guidance: A randomized controlled trial.

Laryngoscope 2016;126:1510-5.


  • Dowrick AS, Wootten AC, Howard N, Peters JS, Murphy DG. A prospective study of the short-term quality-of-life outcomes of patients undergoing transperineal prostate biopsy.

BJU International 2016;118:60-7.


  • Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Lancet Oncology 2016;17:727-37.


  • Falkenberg KJ, Newbold A, Gould CM, et al. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.

Cell Death & Differentiation 2016;23:1209-18.


  • Gaffney DK, King B, Viswanathan AN, et al. Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma.

International Journal of Radiation Oncology, Biology, Physics 2016;95:1191-200.


  • Gandaglia G, Bray F, Cooperberg MR, et al. Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries.

European Urology 2016;69:1013-15.


  • Gandaglia G, Bray F, Cooperberg MR, et al. Prostate Cancer Registries: Current Status and Future Directions.

European Urology 2016;69:998-1012.


  • Gannan E, Khoo J, Nightingale S, et al. Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study.

Breast Journal 2016;22:413-9.


  • Gilan O, Lam EY, Becher I, et al. Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Nature Structural & Molecular Biology 2016;23:673-81.


  • Gray HJ, Benigno B, Berek J, et al. Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.

Journal for ImmunoTherapy of Cancer 2016;4:34.


  • Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Annals of Oncology 2016;27:1047-54.


  • Harrison SJ, Spencer A, Quach H. Myeloma of the central nervous system - an ongoing conundrum!

Leukemia & Lymphoma 2016;57:1505-6.


  • Jayasekara H, Reece JC, Buchanan DD, et al. Risk factors for metachronous colorectal cancer following a primary colorectal cancer: A prospective cohort study.

International Journal of Cancer 2016;139:1081-90.


  • John LB, Darcy PK. The double-edged sword of IFN-gamma-dependent immune-based therapies.

Immunology and Cell Biology 2016;94:527-8.


  • Kron T, Lehmann J, Greer PB. Dosimetry of ionising radiation in modern radiation oncology.

Physics in Medicine and Biology 2016;61:R167-205.


  • Lasocki A, Gaillard F. Ischaemic stroke in the setting of glioblastoma: A case series and review of the literature.

Neuroradiology Journal 2016;29:155-9.


  • Lee B, Wong A, Kee D, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma.

Annals of Oncology 2016;27:1174-7.


  • Martin OA, Yin X, Forrester HB, Sprung CN, Martin RF. Potential strategies to ameliorate risk of radiotherapy-induced second malignant neoplasms.

Seminars in Cancer Biology 2016;37-38:65-76.


  • McBride KA, Schlub TE, Ballinger ML, Thomas DM, Tattersall MH. International survey of awareness of genetic risk in the clinical sarcoma community.

Asia Pacific Journal of Clinical Oncology 2016;12:133-42.


  • Merlino G, Herlyn M, Fisher DE, et al. The state of melanoma: challenges and opportunities.

Pigment Cell Melanoma Research 2016;29:404-16.


  • Michael N, O'Callaghan C, Clayton JM. Exploring the utility of the vignette technique in promoting advance care planning discussions with cancer patients and caregivers.

Patient Education & Counseling 2016;99:1406-12.


  • Mofiz E, Holt DC, Seemann T, Currie BJ, Fischer K, Papenfuss AT. Genomic resources and draft assemblies of the human and porcine varieties of scabies mites, Sarcoptes scabiei var. hominis and var. suis.

Gigascience 2016;5:23.


  • Ngan SY. Preoperative Treatment of Locally Advanced Rectal Cancer: Assets and Drawbacks of Short Course and Long Course in Clinical Practice.

Seminars in Radiation Oncology 2016;26:186-92.


  • Nikesitch N, Tao C, Lai K, et al. Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response.

Blood Cancer Journal 2016;6:e432.


  • Norris BL, Everaerts W, Posma E, et al. The urologist's role in multidisciplinary management of placenta percreta.

BJU International 2016;117:961-5.


  • Ong WL, King K, Koh TL, et al. HIV and renal cell carcinoma: Experience in an Australian statewide HIV center.

Asia Pacific Journal of Clinical Oncology 2016;12:188-93.


  • Pagani O, Regan MM, Francis PA. Are SOFT and TEXT results practice changing and how?

Breast 2016;27:122-5.


  • Pattison S, Mann GB, Crosthwaite G, et al. Predictors of outcome after surgery for gastric cancer in a Western cohort.

ANZ Journal of Surgery 2016;86:469-74.


  • Petitjean C, Setiabakti NM, Mountford JK, Arthur JF, Ellis S, Hamilton JR. Combined deficiency of PI3KC2alpha and PI3KC2beta reveals a nonredundant role for PI3KC2alpha in regulating mouse platelet structure and thrombus stability.

Platelets 2016;27:402-9.


  • Prince HM, Johnstone R. Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Aesthetic Surgery Journal 2016;36:782-3.


  • Roviello G, Sigala S, Sandhu S, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

European Journal of Cancer 2016;61:111-21.


  • Sathianathen NJ, Murphy DG, van den Bergh RC, Lawrentschuk N. Gleason pattern 4: active surveillance no more.

BJU International 2016;117:856-7.


  • Sato T, Paquet-Fifield S, Harris NC, et al. VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury.

Journal of Pathology 2016;239:152-61.


  • Segelov E, Thavaneswaran S, Waring PM, et al. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Journal of Clinical Oncology 2016;34:2258-64.


  • Seymour JF. Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia.

Annals of Hematology 2016;95:1361-2.


  • Shi J, Zhang Y, Zheng W, et al. Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer.

International Journal of Cancer 2016;139:1303-17.


  • Sia J, Moodie K, Bressel M, et al. A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment.

European Journal of Cancer 2016;61:122-7.


  • Steel EJ, Trainer AH, Heriot AG, et al. The Experience of Extended Bowel Resection in Individuals With a High Metachronous Colorectal Cancer Risk: A Qualitative Study.

Oncology Nursing Forum 2016;43:444-52.


  • Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Lancet Oncology 2016;17:768-78.


  • Teh BW, Harrison SJ, Worth LJ, Slavin MA. Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies.

Leukemia & Lymphoma 2016;57:1719-22.


  • Thewes B, Davis E, Girgis A, et al. Routine screening of Indigenous cancer patients' unmet support needs: a qualitative study of patient and clinician attitudes.

International Journal for Equity in Health 2016;15:90.


  • To H, Clemons NJ, Duong CP, Trainer AH, Phillips WA. The Genetics of Barrett's Esophagus: A Familial and Population-Based Perspective.

Digestive Diseases and Sciences 2016;61:1826-34.


  • Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.

World Journal of Urology 2016;34:1031-7.


  • Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavin MA, Thursky KA. Antimicrobial allergy 'labels' drive inappropriate antimicrobial prescribing: lessons for stewardship.

Journal of Antimicrobial Chemotherapy 2016;71:1715-22.


  • Ung KA, Campbell BA, Duplan D, Ball D, David S. Impact of the lung oncology multidisciplinary team meetings on the management of patients                with cancer.

Asia Pacific Journal of Clinical Oncology 2016;12:e298-304.


  • Unsworth A, Anderson R, Haynes N, Britt K. OMIP-032: Two multi-color immunophenotyping panels for assessing the innate and adaptive immune cells in the mouse mammary gland.

Cytometry A 2016;89:527-30.


  • Waldeck K, Cullinane C, Ardley K, et al. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.

International Journal of Cancer 2016;139:194-204.


  • Warrier SK, Heriot AG, Lynch AC. Surgery for Locally Recurrent Rectal Cancer: Tips, Tricks, and Pitfalls.

Clinics in Colon and Rectal Surgery 2016;29:114-22.


  • Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sezary syndrome.

Blood 2016;127:3142-53.


  • Xu W, McArthur G. Cell Cycle Regulation and Melanoma.

Current Oncology Reports 2016;18:34.